Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-01D pediatric phase 1b/2 study of infitamab deruxtecan in relapsed or refractory solid tumors
MOH_2026-06-21_016887Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ifinatamab deruxtecan in Nonhematologic neoplasms, osteosarcoma (OS), neuroblastoma and 2 more (2 arms), sponsored by Merck & Co. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
Nonhematologic neoplasmsosteosarcoma (OS)neuroblastomaWilms' tumorrhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on MOH_2026-06-21_016887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-21_016887.